Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

BD Biosci

Other names: Becton, Dickinson and Company | BD Biosciences | Tripath Oncology | TriPath Oncology, Inc. | TriPath Oncology Inc. | TriPath Oncology Inc | TriPath Imaging | TriPath Oncology, Inc | BD Technologies and Innovation (BDTI) | BD Technologies and Innovation
Related tests:


BD Partners with Camtech Health to increase access to cervical cancer screening in Singapore (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home."
Licensing / partnership
BD Onclarity™ HPV Assay
BD, Techcyte announce strategic collaboration to offer AI-based digital cervical cytology system for Pap testing (BD Bioscience Press Release)
"BD...and Techcyte...announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging...The agreement enables BD to deliver a complete solution that aims to reduce the potential for human error and enable greater throughput, so that labs can achieve their results with greater standardization, reproducibility, and efficiency from a Pap test, also known as a Pap smear."
Licensing / partnership
BD helps advance health equity for women in Kenya through critical cancer screening (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced a collaboration with the Kenyan Government through the National Cancer Institute-Kenya to advance access to critical cancer diagnostics for women in Kenya. Through this program, BD continues to drive its commitment toward progress of advancing health equity to underserved communities around the world."
Licensing / partnership
Becton Dickinson, Navigate BioPharma collaborate on flow cytometry companion diagnostics development (Genomeweb)
"Novartis subsidiary Navigate Biopharma announced...that it has formed a strategic collaboration with Becton Dickinson to help develop and commercialize companion diagnostics and clinical decision-making tools using flow cytometry."
Licensing / partnership
BD Onclarity™ HPV Assay receives FDA approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced U.S. Food and Drug Administration (FDA) market approval for the BD Onclarity™ HPV Assay to be used with the ThinPrep® Pap Test...The inclusion of the ThinPrep® Pap Test improves access to the benefits of the BD human papillomavirus virus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually, and particularly for HPV31, a specific type of HPV that poses a high-risk for causing cervical cancer."
FDA event
BD Onclarity™ HPV Assay
BD, Labcorp collaborate to develop flow cytometry-based companion diagnostics for matching patients with treatments (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced a collaboration agreement with Labcorp...creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases...The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry."
Licensing / partnership
BD expands from cancer discovery and diagnosis into post-treatment monitoring with acquisition of Cytognos from Vitro S.A. (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases...Cytognos' key products increase BD's comprehensive portfolio of diagnostic and research solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosis and understanding, including lymphoma, leukemia and multiple myeloma."